NASDAQ : OBX
Obsidian Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 14.79 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 913.62M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Selling, General & Admin | 17.91M | 19.55M | 18.07M |
| Research & Development | 79.32M | 86.11M | 73.19M |
| Operating Expenses | 97.22M | 105.67M | 91.25M |
| Operating Income | -97.22M | -105.67M | -91.25M |
| Interest & Investment Income | 3.00M | 5.06M | 8.15M |
| Pretax Income | -94.22M | -100.61M | -83.11M |
| Net Income | -94.22M | -100.61M | -83.11M |
| Net Income to Common | -94.22M | -100.61M | -83.11M |
| Shares Outstanding (Basic) | 2.96M | 48.91K | 45.09K |
| Shares Outstanding (Diluted) | 2.96M | 48.91K | 45.09K |
| EPS (Basic) | -31.84 | -2,057.07 | -1,843.10 |
| EPS (Diluted) | -31.84 | -2,057.07 | -1,843.10 |
| Free Cash Flow | -91.83M | -90.47M | -75.78M |
| Free Cash Flow Per Share | -31.03 | -1,849.72 | -1,680.59 |
| EBITDA | -95.86M | -104.18M | -89.73M |
| D&A For EBITDA | 1.37M | 1.48M | 1.53M |
| EBIT | -97.22M | -105.67M | -91.25M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Cash & Equivalents | 17.98M | 40.41M | 49.76M |
| Short-Term Investments | 16.46M | 40.08M | 118.51M |
| Cash & Short-Term Investments | 34.45M | 80.49M | 168.27M |
| Prepaid Expenses | 11.91M | 1.03M | 4.58M |
| Total Current Assets | 46.36M | 81.52M | 172.85M |
| Property, Plant & Equipment | 4.08M | 6.06M | 9.86M |
| Other Long-Term Assets | 1.00M | 1.00M | 1.00M |
| Total Assets | 51.44M | 88.58M | 183.71M |
| Accounts Payable | 365.00K | 12.00K | 1.82M |
| Accrued Expenses | 15.65M | 10.88M | 10.30M |
| Current Portion of Leases | 1.98M | 3.06M | 2.99M |
| Other Current Liabilities | 2.20M | 1.42M | 979.00K |
| Total Current Liabilities | 20.20M | 15.36M | 16.09M |
| Long-Term Leases | 928.00K | 1.22M | 3.82M |
| Other Long-Term Liabilities | 1.00K | 3.00K | 206.00K |
| Total Liabilities | 21.12M | 16.59M | 20.12M |
| Common Stock | 2.00K | 1.00K | 1.00K |
| Additional Paid-In Capital | 41.72M | 29.87M | 20.92M |
| Retained Earnings | -341.43M | -295.94M | -195.33M |
| Comprehensive Income & Other | -3.00K | 23.00K | -27.00K |
| Total Common Equity | -299.71M | -266.04M | -174.43M |
| Shareholders' Equity | 30.32M | 71.99M | 163.60M |
| Total Liabilities & Equity | 51.44M | 88.58M | 183.71M |
| Total Debt | 2.91M | 4.28M | 6.81M |
| Net Cash (Debt) | 31.54M | 76.20M | 161.46M |
| Net Cash Per Share | 10.66 | 1,558.09 | 3,580.59 |
| Filing Date Shares Outstanding | 61.77M | 13.94M | 45.09K |
| Total Common Shares Outstanding | 22.19M | 13.94M | 45.09K |
| Working Capital | 26.16M | 66.15M | 156.76M |
| Book Value Per Share | -13.51 | -19.08 | -3,868.34 |
| Tangible Book Value | -299.71M | -266.04M | -174.43M |
| Tangible Book Value Per Share | -13.51 | -19.08 | -3,868.34 |
| Machinery | 10.78M | 10.70M | |
| Leasehold Improvements | 261.00K | 261.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Net Income | -94.22M | -100.61M | -83.11M |
| Depreciation & Amortization | 1.37M | 1.48M | 1.53M |
| Loss (Gain) From Sale of Investments | -1.40M | -2.61M | -2.21M |
| Stock-Based Compensation | 7.07M | 8.93M | 7.06M |
| Other Operating Activities | -187.00K | -144.00K | -25.00K |
| Change in Accounts Payable | -114.00K | -1.81M | 701.00K |
| Change in Other Net Operating Assets | -4.38M | 4.36M | 1.05M |
| Operating Cash Flow | -91.81M | -90.39M | -75.00M |
| Capital Expenditures | -16.00K | -73.00K | -779.00K |
| Investment in Securities | 74.28M | 81.09M | -53.09M |
| Investing Cash Flow | 74.28M | 81.02M | -53.87M |
| Issuance of Common Stock | 845.00K | 20.00K | 2.55M |
| Other Financing Activities | -532.00K | ||
| Financing Cash Flow | 845.00K | 20.00K | 162.51M |
| Net Cash Flow | -16.68M | -9.36M | 33.64M |
| Free Cash Flow | -91.83M | -90.47M | -75.78M |
| Free Cash Flow Per Share | -31.03 | -1,849.72 | -1,680.59 |
| Levered Free Cash Flow | -52.94M | ||
| Unlevered Free Cash Flow | -52.94M | ||
| Change in Working Capital | -4.50M | 2.56M | 1.75M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Last Close Price | 14.79 | 6.27 | 13.05 |
| Debt / Equity Ratio | 0.10 | 0.06 | 0.04 |
| Net Debt / Equity Ratio | -1.04 | -1.06 | -0.99 |
| Net Debt / EBITDA Ratio | 0.33 | 0.73 | 1.80 |
| Net Debt / FCF Ratio | 0.34 | 0.84 | 2.13 |
| Quick Ratio | 1.71 | 5.24 | 10.46 |
| Current Ratio | 2.29 | 5.31 | 10.74 |
| Return on Equity (ROE) | -85.41% | ||
| Return on Assets (ROA) | -48.51% | ||
| Return on Capital Employed (ROCE) | -311.20% | -144.30% | -54.40% |
| Buyback Yield / Dilution | -8.46% |